CFDA Proposes Draft Lowering Barriers for Foreign Drug Manufacturers
In March 2017, the China Food and Drug Administration (CFDA) has released draft rules allowing MNCs to include Chinese patients in the earliest possible stages of drug multi-regional clinical trials (MRCTs). These policies are meant to significantly reduce foreign drug registration timelines.... Read More